Wells Fargo & Company Boosts HCA Healthcare (NYSE:HCA) Price Target to $395.00

HCA Healthcare (NYSE:HCA) had its price objective hoisted by Wells Fargo & Company from $365.00 to $395.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have an equal weight rating on the stock.

A number of other research analysts also recently issued reports on the company. Royal Bank of Canada upped their price target on HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Friday, August 23rd. Truist Financial lifted their price target on shares of HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. UBS Group lifted their target price on shares of HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. StockNews.com upgraded HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 1st. Finally, Oppenheimer increased their target price on HCA Healthcare from $345.00 to $390.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $367.15.

HCA Healthcare Stock Performance

Shares of HCA Healthcare stock opened at $398.90 on Tuesday. The company has a debt-to-equity ratio of 27.11, a current ratio of 1.06 and a quick ratio of 0.94. The stock has a market cap of $104.48 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 1.44 and a beta of 1.67. HCA Healthcare has a 1 year low of $220.55 and a 1 year high of $417.14. The firm’s 50-day moving average is $394.72 and its 200 day moving average is $352.30.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported $5.50 earnings per share for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53. The company had revenue of $17.49 billion during the quarter, compared to analyst estimates of $17.05 billion. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $4.29 EPS. Sell-side analysts anticipate that HCA Healthcare will post 22.51 EPS for the current fiscal year.

Insider Transactions at HCA Healthcare

In related news, SVP Kathleen M. Whalen sold 2,987 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $363.51, for a total value of $1,085,804.37. Following the transaction, the senior vice president now directly owns 9,454 shares of the company’s stock, valued at approximately $3,436,623.54. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Kathleen M. Whalen sold 2,987 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $363.51, for a total value of $1,085,804.37. Following the transaction, the senior vice president now owns 9,454 shares of the company’s stock, valued at approximately $3,436,623.54. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of HCA Healthcare stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the sale, the executive vice president now owns 29,678 shares in the company, valued at approximately $11,438,494.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,345 shares of company stock valued at $5,747,945 over the last 90 days. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HCA. Capital World Investors grew its stake in shares of HCA Healthcare by 57.5% in the 1st quarter. Capital World Investors now owns 2,792,377 shares of the company’s stock worth $931,342,000 after buying an additional 1,019,750 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in HCA Healthcare during the second quarter valued at approximately $131,527,000. Darsana Capital Partners LP increased its position in shares of HCA Healthcare by 53.3% during the 2nd quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company’s stock valued at $369,472,000 after purchasing an additional 400,000 shares during the last quarter. Swedbank AB purchased a new position in HCA Healthcare during the first quarter worth $95,882,000. Finally, TD Asset Management Inc raised its stake in shares of HCA Healthcare by 30.4% in the first quarter. TD Asset Management Inc now owns 721,318 shares of the company’s stock valued at $240,581,000 after acquiring an additional 168,093 shares during the period. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.